| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 28(4); 1996 > Article
Journal of the Korean Cancer Association 1996;28(4): 739-748.
고용량 Cisplatin 복합화학요법시 발생하는 급성 구토의 예방에 대한 Granisetron 과 Dexamethasone 및 Ondansetron 과 Dexamethasone 병용요법의 비교 연구
이정애, 박영석, 우인숙, 박영이, 선덕재, 김정아, 윤성수, 강원기, 박근칠, 박찬형
A Randomized comparison of Granisetron Plus Dexamethasone and Ondansetron Plus Dexamethasone in the Prevention of High - dose Cisplatin - indu
Jung Ae Rhee, Young Suk Park, In Sook Woo, Young Iee Park, Duk Jhe Shun, Jeong A Kim, Sung Soo Yoon, Won Ki Kang, Keunchil Park, Chan Hyung Park
We report the prospective, randomized clinical study comparing granisetron and ondansetron as antiemetics in cancer chemotherapy. This study compares the efficacy and safety of a single dose of granisetron plus dexamethasone(GD) with three doses of ondansetron plus dexamethasone(OD) in the prevention of acute emesis induced by chemotherapy. One hundred one chemotherapy-native patients who received high dose ciaplatin(¡Al00mg /§³)-based combination chemotherapy were stratified by chemotherapeutic regimen. Patients were randomized to receive either 3 mg of granisetron intravenously(i.v.) or 8 mg of ondansetron for three doses i.v. in combination with dexamethasone to prevent emesis in the first 24 hours. In the GD group, a complete response(CR)(i.e., no emetic episode) was achived in 57% cases and a major response(MR)(i.e. ¡A2 emetic episodes) in 24%. In the OD group, a CR was seen in 71% of patients and an MR in 25%. Failure was recored in 7% and 2% of cases in the GD and OD, respectively. No statistically significant difference in any response category was seen between the two groups. Both GD and OD were well tolerated with no severe or unexpected side effects. In summary, these data suggest that single daily dose of granisetron(3mg/day) appeared similarly effective and well tolerated to three daily doses of ondansetron(8mg three times daily) in prevention of acute emesis induced by high dose cisplatin-based combination chemotherapy.
Key words: Granisetron, Ondansetron, Dexamethasone, High dose cisplatin-base combination chemotherapy
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI